Keywords: Vertex, Kalydeco, Cyctic fibrosis, NDA, USA, FDA

Vertex files for US priority review and approval of Kalydeco for cystic fibrosis

Article | 20 October 2011

Print This

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) says it has filed a New Drug Application with the Food and Drug Administration for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in